Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL). J of Skin. 2020;4(5):s51. doi:10.25251/skin.4.supp.50